Zacks Investment Research Upgrades Koninklijke DSM (OTCMKTS:RDSMY) to “Buy”

Koninklijke DSM (OTCMKTS:RDSMY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, reports. The brokerage presently has a $45.00 price target on the basic materials company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 11.11% from the stock’s current price.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

RDSMY has been the subject of several other reports. Credit Suisse Group restated a “neutral” rating on shares of Koninklijke DSM in a report on Wednesday, July 15th. UBS Group reissued a “buy” rating on shares of Koninklijke DSM in a research note on Wednesday, July 8th. Main First Bank upgraded shares of Koninklijke DSM from a “hold” rating to a “buy” rating in a report on Friday, July 24th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Koninklijke DSM in a research note on Monday, June 29th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $45.00.

Shares of OTCMKTS RDSMY opened at $40.50 on Tuesday. The firm has a 50 day moving average price of $39.15 and a 200 day moving average price of $33.26. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.30 and a current ratio of 2.09. The stock has a market cap of $29.39 billion, a P/E ratio of 41.33, a P/E/G ratio of 2.58 and a beta of 1.02. Koninklijke DSM has a 52-week low of $22.86 and a 52-week high of $40.76.

Koninklijke DSM (OTCMKTS:RDSMY) last announced its quarterly earnings results on Tuesday, August 4th. The basic materials company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.02). Koninklijke DSM had a net margin of 6.97% and a return on equity of 10.20%. The firm had revenue of $2.46 billion during the quarter. Analysts predict that Koninklijke DSM will post 1.32 earnings per share for the current fiscal year.

About Koninklijke DSM

Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and materials businesses in the Netherlands, North America, the United Kingdom, France, Germany, Switzerland, the Asia-Pacific, and internationally.. The company operates through Nutrition, Materials, and Innovation Center segments.

Featured Story: What is a front-end load?

Get a free copy of the Zacks research report on Koninklijke DSM (RDSMY)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Koninklijke DSM (OTCMKTS:RDSMY)

Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with's FREE daily email newsletter.